{"filings":[{"id":78201,"accession_number":"0001824293-26-000046","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2026-05-14T12:36:07+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"GRI Bio Q1 net loss $2.0M; Phase 2a data show zero cough, improved lung function in IPF","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.0M for Q1 2026 vs. $3.0M in Q1 2025; cash $11.0M, runway into Q2 2027.","Phase 2a of GRI-0621 in IPF: zero cough in active arm vs 25% placebo; 61% less diarrhea vs placebo despite 67% more nintedanib use.","Exploratory FVC improvement: +99 mL overall, +139 mL in SOC combination subset vs placebo+SOC.","Raised ~$6.8M gross via ATM facility in Q1 2026; advancing GRI-0621 toward pivotal studies, GRI-0803 toward IND.","No SAEs in active arm; single SAE in placebo; patent applications filed based on new data."],"consensus_eps_estimate":-0.9141,"consensus_eps_actual":-1.61,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109239,"accession_number":"0001824293-26-000040","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2026-02-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRI Bio reiterates FY2025 results: $8.2M cash, $12M loss; raises $6.5M, runway into Q1 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and cash equivalents of $8.2M at Dec 31, 2025; raised additional $6.5M in Jan 2026 via ATM offering.","Net loss for FY2025 was $12M; R&D expenses increased to $6.8M from $3.8M year-over-year.","Cash runway expected to fund planned operations into the first quarter of 2027.","Positive Phase 2a data for GRI-0621 in idiopathic pulmonary fibrosis reinforces clinical proof-of-concept.","Advancing GRI-0803 for autoimmune indications through IND-enabling studies."],"consensus_eps_estimate":-29.5526,"consensus_eps_actual":-121.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109238,"accession_number":"0001824293-26-000030","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2026-01-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GRI Bio expands ATM equity offering capacity from $10M to $60M via H.C. Wainwright amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment to At The Market Offering Agreement increases aggregate offering price to $60 million.","Prior cap was $10 million; amended agreement effective January 28, 2026.","Waivers obtained from December 2025 Securities Purchase Agreement investor to permit ATM issuances.","Prospectus supplement filed Jan 29, 2026 to register up to $60M of common stock.","Sales agent remains H.C. Wainwright & Co., LLC; shares sold at market prices."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109237,"accession_number":"0001824293-26-000017","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2026-01-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio reports positive Phase 2a gene expression data for GRI-0621 in IPF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a gene expression data shows significant improvements in lung injury, fibroblast activation, and fibrosis-resolution genes vs placebo.","Data support basement membrane repair and AT2-to-AT1 epithelial cell transition, suggesting lung regeneration.","GRI-0621 met primary safety endpoint and multiple secondary endpoints; exploratory FVC improved vs standard of care.","CEO states data exceed expectations, reinforcing potential as a disease-modifying therapy for IPF."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109236,"accession_number":"0001824293-26-000014","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2026-01-21T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"GRI Bio announces 1-for-28 reverse stock split effective Jan 23, 2026 to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved reverse split at January 15, 2026 special meeting.","Outstanding shares to reduce from ~15,016,434 to ~536,301; authorized shares unchanged.","Cash in lieu of fractional shares at closing price on Jan 23, 2026.","Proportional adjustments to options, warrants, convertible securities and stock plans.","Trading to begin on split-adjusted basis on Nasdaq under ticker 'GRI' on Jan 26, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109235,"accession_number":"0001824293-26-000011","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2026-01-16T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GRI Bio conditionally regains Nasdaq equity compliance after prior deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq Staff notified GRI Bio on Jan 15, 2026 that it conditionally regained compliance with the Stockholders' Equity Requirement (Nasdaq Listing Rule 5550(b)(1)).","The requirement mandates at least $2.5 million in stockholders' equity for companies with market value under $35 million and annual net income below $500,000.","Non-compliance was previously reported in a Dec 2, 2025 8-K based on the Sept 30, 2025 10-Q.","If future Exchange Act reports fail to show compliance, common stock may again face delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109234,"accession_number":"0001824293-26-000009","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2026-01-15T23:59:59+00:00","items":["5.07","8.01"],"status":"ready","headline":"GRI Bio shareholders approve reverse stock split; company addresses Nasdaq equity deficiency with $8M offering","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Shareholders approved reverse stock split at ratio between 1:2 and 1:30, with board discretion to set exact ratio or abandon.","Company received Nasdaq deficiency notice on Nov 26, 2025 for stockholders' equity below $2.5M.","Dec 12, 2025 public offering raised ~$8.0M gross proceeds, bringing equity above the $2.5M minimum.","Nasdaq will monitor compliance at next periodic report; failure may lead to delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109233,"accession_number":"0001824293-26-000006","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio increases ATM offering capacity to $7.38M, waives Dec 2025 SPA restrictions","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased ATM capacity by up to $7.38M in common stock; $6.17M already sold under the program.","Waived certain provisions of the Dec 11, 2025 securities purchase agreement to permit additional ATM issuances.","At-the-market offering agreement with H.C. Wainwright & Co. dated May 20, 2024 remains in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109232,"accession_number":"0001824293-26-000002","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio reports positive Phase 2a immune data for GRI-0621 in IPF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a data shows GRI-0621 reduces pro-fibrotic cytokines (IL-4, IL-13, IL-17A, IL-22, TGF-β) and increases anti-fibrotic IFN-γ in BAL and PBMC after 12 weeks.","Study met primary safety/tolerability endpoint; secondary endpoints suggest fibrosis reversal and lung repair, with twice as many subjects with no FVC decline vs standard of care.","35 subjects enrolled, 2:1 randomized to GRI-0621 4.5mg or placebo for 12 weeks; sub-study in 8 subjects examines immune cells in BAL fluid.","Company believes stockholders' equity exceeds $2.5M Nasdaq minimum after December 2025 public offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125732,"accession_number":"0001628280-25-056751","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio closes $8.0M public offering of common stock and Series F warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 10,666,667 shares (or equivalents) plus Series F warrants to buy same number at $0.75/share.","Gross proceeds $8.0M; H.C. Wainwright acted as exclusive placement agent.","Series F warrants exercisable immediately at $0.75, expire in five years; potential additional $8.0M if fully cash-exercised.","Proceeds to fund product development, working capital, and general corporate purposes.","Post-offering stockholders' equity exceeds $2.5 million, addressing Nasdaq continued listing requirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125731,"accession_number":"0001628280-25-056659","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-12-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GRI Bio launches $6.7M public offering of common stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering comprises 2.6M shares, 8.1M pre-funded warrants ($0.0001/share), and 10.7M Series F warrants ($0.75/share) at $0.75 per unit.","Net proceeds expected ~$6.7M; funds working capital, product development, and general corporate purposes.","Closing anticipated December 12, 2025; H.C. Wainwright acts as placement agent with 7.0% cash fee plus warrants.","Company believes proceeds plus existing cash will fund operations into Q4 2026; 60-day lockup on further equity issuance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125730,"accession_number":"0001824293-25-000167","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-12-10T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio announces positive Phase 2a topline results for GRI-0621 in IPF","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint met: GRI-0621 well tolerated with no drug-related severe/serious adverse events; no GI increase vs placebo.","Biomarkers improved: type VI collagen remodeling shifted from fibrogenic (+10%) to fibrolytic (-7%), suggesting fibrosis resolution.","FVC improved: placebo-adjusted increase of 99ml (139ml with standard of care); 39% of GRI-0621 subjects gained FVC vs 80% of placebo declined.","Type IV collagen remodeling shifted to neutral (0%) vs fibrolytic (-16%) in placebo, indicating alveolar basement membrane repair."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125729,"accession_number":"0001824293-25-000160","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"GRI Bio reports positive Phase 2a data for GRI-0621 in IPF; primary endpoint met","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2a trial (35 IPF subjects, 2:1 randomization) met primary safety endpoint; GRI-0621 well tolerated over 12 weeks with no treatment-related SAEs.","Placebo-adjusted FVC increased 99 ml (all treated) and 139 ml (on top of standard of care); 39% of treated had FVC gain vs 80% decline on placebo.","Serum biomarkers showed anti-fibrotic effect (decreased fibrosis markers, increased resolution markers) and alveolar basement membrane repair signals.","Adverse events were grade 2 (17%) or grade 3 (4%); common: dry skin, dry lips, muscle pain; no cough or GI increase vs placebo.","80% of subjects on background pirfenidone/nintedanib; no changes in liver enzymes, triglycerides or cholesterol observed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125728,"accession_number":"0001824293-25-000155","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GRI BIO receives Nasdaq delisting notice for stockholders' equity deficiency","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified GRI BIO of non-compliance with minimum stockholders' equity requirement (Listing Rule 5550(b)(1)).","As of September 30, 2025, stockholders' equity fell below the required $2.5M threshold.","Company has 45 days (until January 10, 2026) to submit a plan to regain compliance.","If plan accepted, Nasdaq may grant up to 180 additional calendar days to cure the deficiency.","Failure to regain compliance or rejection of plan may lead to delisting; company can appeal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142455,"accession_number":"0001824293-25-000126","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-08-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GRI Bio files corporate presentation with no material new disclosures","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Furnished a corporate presentation dated August 20, 2025 under Regulation FD.","Presentation provides an overview of GRI Bio's approach to inflammatory diseases.","No specific financial results, guidance, or material operational updates were disclosed.","The filing is made under Item 7.01 and is not deemed filed for SEC purposes.","Ticker: GRI; stock trades on Nasdaq Capital Market."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142454,"accession_number":"0001824293-25-000096","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve 400,000-share increase to GRI Bio's 2018 Equity Incentive Plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders voted 48,362 to 17,889 (179 abstain) to approve the amendment; broker non-votes: 1,023,943.","Plan increase: 400,000 additional shares of common stock reserved for issuance under the Amended and Restated 2018 Equity Incentive Plan.","Approximately 43.67% quorum (1,090,373 of 2,496,800 eligible shares) was present at the virtual August 13, 2025 Annual Meeting.","Directors Roelof Rongen and Camilla V. Simpson elected with 63,031 and 63,581 votes for, respectively (broker non-votes: 1,023,943 each).","Ratification of WithumSmith+Brown as auditor: 1,072,167 for, 16,553 against, 1,653 abstain (no broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":142453,"accession_number":"0001824293-25-000094","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-07-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio reports positive interim biomarker data from Phase 2a IPF study; IDMC recommends continuation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["6-week interim data from Phase 2a study of GRI-0621 in IPF show reduced fibrogenesis and increased fibrolysis in treated patients.","IDMC recommended study continue as planned; no safety concerns seen to date.","Phase 2a study fully enrolled; topline data expected Q3 2025.","GRI-0621 patients demonstrated increased basement membrane remodeling and potential repair mechanism vs control.","Additional pulmonary function test results expected in coming weeks; flow cytometry and gene expression data later."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160499,"accession_number":"0001824293-25-000082","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-06-26T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"GRI Bio reports positive interim safety results from Phase 2a IPF study; IDMC recommends continuation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IDMC recommends study continue after no safety concerns in first 24 patients evaluated at 6 weeks.","GRI-0621 safe and well-tolerated; no adverse events related to hyperlipidemia (LDL, HDL, TG).","No clinically meaningful changes in HDL, LDL, or TG levels; all subjects within protocol ranges.","Interim biomarker data expected July 2025; topline results from Phase 2a study expected Q3 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160498,"accession_number":"0001824293-25-000079","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio increases ATM offering capacity by $1.76M after selling $4.55M previously","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed prospectus supplement to increase maximum shares issuable under ATM to $1,758,934.","Previously sold ~$4,546,137 in shares under May 2024 Sales Agreement with H.C. Wainwright.","Total potential gross proceeds under the ATM program now approximately $6.3 million.","Shares to be sold at market prices; proceeds for general corporate purposes.","Legal opinion on share issuance from Mintz Levin attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160497,"accession_number":"0001824293-25-000072","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRI Bio reports Q1 net loss $3.0M; GRI-0621 Phase 2a IPF trial on track for data in Q2/Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $3.0M for Q1 2025; R&D expenses $1.6M, G&A $1.4M.","Cash $3.3M at March 31; subsequent $5M public offering; cash runway expected through Q3 2025.","Phase 2a trial of GRI-0621: 6-week interim data (n=24) expected Q2 2025; topline data Q3 2025.","Interim 2-week data in first 12 patients showed safety, no hyperlipidemia, and biomarker PRO-C3 suggestive of anti-fibrotic effect.","Enrollment over two-thirds complete for overall Phase 2a IPF trial."],"consensus_eps_estimate":null,"consensus_eps_actual":-5.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160496,"accession_number":"0001824293-25-000063","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio increases ATM offering capacity by up to $1.67M, on top of $3.6M already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prospectus supplement filed to increase ATM issuance by up to $1.67M, on top of $3.6M previously sold.","Shares sold to date total $3,604,683; new maximum of $1,670,956 does not include prior sales.","ATM sales agreement with H.C. Wainwright dated May 20, 2024; offering of common stock provides incremental equity financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160495,"accession_number":"0001824293-25-000058","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-04-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"GRI Bio dismisses auditor Sadler Gibb, appoints WithumSmith+Brown as new independent accountant.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit Committee dismissed Sadler Gibb on April 11, 2025; no disagreements on accounting principles or practices.","Previously reported material weakness in internal control over warrant accounting; no restatements required.","Sadler's reports for FY2024 and FY2023 included a going concern explanatory paragraph but no adverse opinion.","WithumSmith+Brown appointed as independent registered public accounting firm for FY2025.","Sadler furnished a letter to the SEC, filed as Exhibit 16.1, agreeing with the company's disclosures."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":160494,"accession_number":"0001628280-25-016066","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-04-02T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"GRI Bio prices $5M public offering of shares and warrants; net proceeds ~$4.2M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Priced public offering of 1,388,888 units at $3.60 each (share or pre-funded warrant plus Series E-1, E-2, E-3 warrants).","Gross proceeds ~$5.0M; net ~$4.2M after 7% agent fee and expenses; closing expected April 2, 2025.","Warrants exercisable at $3.20; if fully cash-exercised, additional gross proceeds ~$13.3M.","Net proceeds for working capital and product development; cash runway expected only through Q3 2025.","H.C. Wainwright acting as placement agent; receives warrants for 97,222 shares at $4.50 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178747,"accession_number":"0001824293-25-000053","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRI Bio reports FY2024 net loss of $8.2M; cash runway into Q2 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $8.2M for FY2024; R&D spend increased 19% to $3.8M; G&A fell 45% to $4.5M.","Cash and equivalents of $5.0M at Dec 31, 2024; runway only into Q2 2025 (through interim data).","Phase 2a interim data for GRI-0621 in IPF expected Q2 2025; topline results Q3 2025.","European patent granted for GRI-0803 and library of 500+ proprietary NKT cell modulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178746,"accession_number":"0001824293-25-000045","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-03-11T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"GRI Bio regains compliance with Nasdaq minimum bid price rule","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on March 10, 2025 confirming compliance with Listing Rule 5550(a)(2).","Previously reported bid price deficiency in September 2024 filings.","Company is now in full compliance and subject to no further action from Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178745,"accession_number":"0001824293-25-000042","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-02-19T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"GRI Bio announces 1-for-17 reverse stock split effective Feb 21, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1:17 ratio, effective 4:01 p.m. ET on Feb 21, 2025; post-split trading begins Feb 24, 2025 on Nasdaq under symbol GRI.","Outstanding shares will decrease from ~8.93 million to ~525,492; authorized share count unchanged.","Reverse split is intended to regain compliance with Nasdaq minimum bid price requirement.","Proportional adjustments will be made to exercise prices and shares for stock options, warrants, and convertible securities.","No fractional shares issued; cash payment in lieu based on closing price on Feb 21, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178744,"accession_number":"0001824293-25-000039","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2025-02-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GRI Bio shareholders authorize reverse stock split at ratio of 1:2 to 1:23","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Feb 11, 2025; quorum of 4,640,469 shares (51.94%) present.","Reverse split proposal approved: 3,151,775 for, 1,484,078 against, 4,616 abstain.","Board may set exact ratio within 1:2 to 1:23 range and can abandon split entirely.","Adjournment proposal also approved: 3,237,240 for, 1,390,423 against, 12,806 abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195423,"accession_number":"0001824293-24-000159","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio increases at-the-market offering capacity to $322,468 after $3.6M already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["On December 20, 2024, GRI Bio filed a prospectus supplement to increase shares issuable under its ATM agreement with H.C. Wainwright to up to $322,468.","The company had previously sold approximately $3,604,683 of shares under the same Sales Agreement dated May 20, 2024.","An opinion from Mintz, Levin law firm on the legality of the share issuance was attached as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195422,"accession_number":"0001824293-24-000153","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRI Bio reports Q3 net loss of $6.3M; cash runway extended into mid Q1 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $6.3M for nine months ended Sep 30, 2024; R&D expenses $2.9M.","Cash and cash equivalents $4.7M as of Sep 30, 2024.","Raised $13.9M gross proceeds since start of 2024, extending runway into mid Q1 2025.","Interim data from GRI-0621 Phase 2a biomarker study expected Q1 2025; topline Q2 2025.","Preclinical data presented; Japan patent granted; Australian study authorization received."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.56,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195421,"accession_number":"0001824293-24-000143","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-10-24T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio raises $13.9M in gross proceeds since Jan 2024; cash runway into mid Q1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed Oct 22 warrant exercise for 762,236 shares raising $0.8M gross proceeds.","Total gross proceeds since start of 2024 are approximately $13.9M.","Cash runway estimated into mid Q1 2025, supporting Phase 2a interim data for GRI-0621 (IPF).","Issued new Series D-1 and D-2 warrants with exercise price of $1.00 per share.","H.C. Wainwright acted as exclusive placement agent for the offering."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":195420,"accession_number":"0001824293-24-000141","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-10-22T23:59:59+00:00","items":["1.01","3.02","3.03","8.01","9.01"],"status":"ready","headline":"GRI Bio amends warrants; raises $0.8M by reducing exercise price to $1.00","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered repricing agreements for 762,236 Series B warrants; holders exercise at $1.00/share (down from $14.30) for gross proceeds of $762,236.","Issued new Series D-1 (5-year term) and Series D-2 (18-month term) warrants, also exercisable at $1.00/share.","Net proceeds to be used for working capital and general corporate purposes; offering closed October 22, 2024.","H.C. Wainwright acted as placement agent, receiving 7% cash fee plus 1% management fee and warrants to purchase 53,357 shares at $1.25.","New warrants and shares issued in unregistered private placement under Section 4(a)(2) and Regulation D; resale registration to be filed within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211681,"accession_number":"0001824293-24-000133","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GRI Bio receives Nasdaq deficiency notice for minimum bid price non-compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Sept 10, 2024; closing bid price below $1.00 for 30 consecutive business days.","Has 180 calendar days (until March 10, 2025) to regain compliance by closing at $1.00 for 10 consecutive business days.","If stock closes at $0.10 or less for 10 consecutive days before compliance date, Nasdaq will issue delisting determination.","Company monitoring options to regain compliance; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211674,"accession_number":"0001824293-24-000138","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K/A","filed_at":"2024-09-11T23:59:59+00:00","items":["5.07","3.01"],"status":"ready","headline":"GRI Bio receives Nasdaq deficiency notice for bid price below $1; 180-day cure period until March 10, 2025","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Sept 10, 2024 for failing minimum bid price of $1.00 over 30 consecutive business days.","Has until March 10, 2025 (180 days) to regain compliance by closing at $1.00+ for 10 consecutive business days.","If stock closes at $0.10 or less for 10 consecutive trading days during cure period, Nasdaq may issue delisting determination.","Company may be eligible for an additional 180-day extension if it meets other Nasdaq listing conditions.","Management is monitoring the bid price and evaluating options to regain compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211680,"accession_number":"0001824293-24-000129","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-09-06T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GRI Bio shareholders reject equity plan increase by 600K shares; director David Baker elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David Baker elected Class I director with 61,134 for vs 40,091 against (155 abstain).","Ratification of Sadler, Gibb & Associates as auditor passed: 285,641 for, 25,988 against.","Proposal to issue shares underlying warrants (Nasdaq Rule 5635(d)) passed: 51,165 for, 47,971 against.","Amendment to 2018 Equity Incentive Plan to add 600,000 shares failed: 31,556 for, 68,911 against.","Quorum of 311,668 shares (42% of eligible) present at reconvened annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211679,"accession_number":"0001824293-24-000116","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-08-23T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GRI Bio adjourns 2024 annual meeting to Sept 6 to solicit more proxies for outstanding proposals","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Only 34.58% of shares present (256,566 of 741,914); quorum was barely met at one-third threshold.","Adjournment proposal passed with 157,455 for, 99,095 against, 16 abstain; no broker non-votes.","Meeting adjourned to September 6, 2024 at 11 a.m. ET; voting on other agenda items postponed.","Company plans to solicit additional proxies to adopt remaining proposals from the proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211678,"accession_number":"0001824293-24-000107","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"GRI Bio Q2 net loss $2.4M; cash runway into Q1 2025; Phase 2a IPF data on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $2.4M for Q2 2024; R&D expense $0.9M; G&A expense $1.4M (down from $5.1M YoY).","Cash and equivalents $6.4M as of June 30, 2024; public offering in June raised $4.0M gross.","Cash expected to fund operations into Q1 2025; plans to raise additional funds.","GRI-0621 Phase 2a IPF biomarker study: interim data Q4 2024, topline data Q1 2025.","GRI-0803 SLE program progressing preclinically; IND-enabling contingent on funding."],"consensus_eps_estimate":null,"consensus_eps_actual":-8.82,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211677,"accession_number":"0001824293-24-000094","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-07-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio increases ATM offering capacity to $2.64M, reports $961K already sold","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Maximum aggregate gross proceeds from ATM offering raised to $2,644,609 via prospectus supplement filed July 26, 2024.","Approximately $961,272 of shares have already been sold under the May 20, 2024 Sales Agreement with H.C. Wainwright & Co.","Shares are common stock, par value $0.0001 per share; proceeds used for general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211676,"accession_number":"0001824293-24-000084","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-07-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"GRI Bio increases ATM offering capacity by up to $1.04M, excluding prior $0.96M sales","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Increased maximum aggregate sales price of shares under ATM agreement with H.C. Wainwright to $1,038,886, excluding $961,272 already sold.","ATM agreement originally dated May 20, 2024; prospectus supplement filed July 19, 2024.","Shares to be issued are common stock, par value $0.0001 per share; legal opinion from Mintz, Levin filed as exhibit."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211675,"accession_number":"0001824293-24-000078","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-07-08T23:59:59+00:00","items":["3.01","8.01","9.01"],"status":"ready","headline":"GRI Bio regains compliance with Nasdaq continued listing standards","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on July 2, 2024 curing equity deficiency under Listing Rule 5550(b).","Scheduled hearing before Nasdaq Hearings Panel has been canceled.","Now in compliance with all applicable continued listing standards on Nasdaq Capital Market.","No financial impact or operational changes disclosed; CEO expresses focus on core business."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230414,"accession_number":"0001628280-24-030244","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-06-27T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"GRI Bio prices $4.0M public offering of shares and warrants at $1.83/unit","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 2,185,793 shares (or equivalents) plus Series C-1 and C-2 warrants at $1.83 per unit.","Gross proceeds ~$4.0M, net proceeds ~$3.2M after 7% placement agent fee and expenses.","Warrants exercisable at $1.83/share upon stockholder approval; C-1 expires 5 yrs, C-2 expires 18 months.","Proceeds allocated to product candidate development, working capital, and general corporate purposes.","H.C. Wainwright is exclusive placement agent; closing expected on or about June 28, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230413,"accession_number":"0001824293-24-000070","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-06-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"GRI Bio CMO Albert Agro reduced to 70 hrs/month, salary cut to $100k","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CMO Albert Agro's base salary reduced from $325,000 to $100,000 annually.","Agro now required to work at least 70 hours per month, may take other consulting work.","Annual cash performance bonus and severance upon termination without cause eliminated.","Employment now terminable by either party with 30 days' notice; no severance benefits.","Effective June 17, 2024; amendment filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230412,"accession_number":"0001824293-24-000060","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["3.03","5.03","8.01","9.01"],"status":"ready","headline":"GRI Bio announces 1-for-13 reverse stock split to regain Nasdaq compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split at 1-for-13 effective 4:01 p.m. ET June 17, 2024; split-adjusted trading starts June 18, 2024.","Approximately 6.6M pre-split shares reduce to about 508K post-split shares; no change to authorized shares.","Purpose is to boost per-share price to satisfy Nasdaq minimum bid price requirement for continued listing.","No fractional shares issued; cash in lieu based on June 17 closing price; CUSIP changes to 3622AW 304.","Proportional adjustments made to options, warrants, and convertible securities exercise prices and share counts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230411,"accession_number":"0001824293-24-000057","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"GRI Bio stockholders approve reverse stock split in range of 1:2 to 1:15","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 approved: 1,417,003 votes for, 310,490 against, 120 abstained.","Board authorized to set exact ratio between 1:2 and 1:15; may still abandon split.","Proposal 2 (adjournment) approved with 1,427,587 for, 270,321 against, 29,705 abstained.","Special meeting held June 7, 2024; quorum of 1,727,613 shares (45.8%) present."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230410,"accession_number":"0001824293-24-000055","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"GRI Bio receives Nasdaq delisting determination; plans to appeal by May 28, 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq Staff determination letter on May 21, 2024, for non-compliance with stockholders' equity rule (Rule 5550(b)) after initial 180-day cure period ended May 20, 2024.","Despite reporting >$2.5M equity as of March 31, 2024, Nasdaq considered historical burn rate and concluded non-compliance.","Company intends to request a hearing before a Nasdaq Hearings Panel by May 28, 2024, which will automatically stay suspension/delisting pending outcome.","Panel may grant up to 180-day extension, but no guarantee of regaining compliance or continued listing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230409,"accession_number":"0001824293-24-000052","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-05-20T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"GRI Bio enters into ATM equity offering agreement with H.C. Wainwright for up to $961,579","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company may sell up to $961,579 of common stock through H.C. Wainwright as sales agent.","Wainwright receives 3% commission on gross proceeds; no obligation for Company to sell.","Shares offered on Nasdaq as at-the-market sales under May 20, 2024 prospectus supplement.","Company can suspend or terminate the agreement at any time; $10M aggregate cap also applies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230408,"accession_number":"0001824293-24-000049","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["2.02","7.01","9.01"],"status":"ready","headline":"GRI Bio reports Q1 net loss $1.9M; cash $4.1M; Phase 2a IPF study interim data due Q3 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $1.9M for Q1 2024; R&D expenses $0.9M, G&A $1.0M.","Cash and equivalents $4.1M as of March 31, 2024; public offering raised $5.5M gross in Feb 2024.","GRI-0621 Phase 2a biomarker study in IPF: interim data Q3 2024, topline results Q4 2024.","GRI-0803 for SLE: IND-enabling studies to complete Q3 2024; IND filing expected H2 2024.","Expanded IP estate with Korean patent issuance and Canadian notice of allowance for NKT cell modulators."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":230407,"accession_number":"0001824293-24-000037","cik":1824293,"company_name":"GRI Bio, Inc.","ticker":"GRI","form_type":"8-K","filed_at":"2024-04-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"GRI Bio reports FY2023 net loss of $13.0M; cash runway extended into Q3 2024 after $5.5M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.0M for FY2023; R&D expense $3.2M (up from $0.2M) and G&A $8.2M (up from $2.0M).","Cash and equivalents $1.8M as of Dec 31, 2023; subsequent Feb 2024 public offering raised $5.5M.","Phase 2a biomarker study for lead IPF drug GRI-0621 ongoing; interim data H1 2024, topline H2 2024.","GRI-0803 for SLE completing IND-enabling studies; IND filing on track for H1 2024.","Received notice of allowance for Canadian patent covering proprietary NKT cell modulators."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.46,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":3789239.356190476,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}